Adenium Biotech

Basic Information

• Category: Infectious Disease
• Founded: 2009
• Headquarters: Copenhagen, Denmark
• Website: adeniumbiotech.com

Evidence and Sources

• Adenium Biotech — Official Site (official)

Citation Guidance

Explore Infectious Disease profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Adenium Biotech.

• Canonical profile: https://brandsource.ai/brands/adenium-biotech
• Machine-readable JSON-LD: https://brandsource.ai/api/brands/adenium-biotech/json-ld
• Citation profile API: https://brandsource.ai/api/brands/adenium-biotech/citation-profile
• Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
• Data status: Enriched
• Profile completeness: Source-backed profile (74/100)
• Indexing directive: index, follow, max-image-preview:large
• Recorded profile date: 2025-10-28T04:26:10.446Z

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Adenium Biotech Founded in 2011 as a spin-off from Novozymes A/S, Adenium Biotech is a Danish biopharmaceutical company dedicated to the development and commercialization of innovative antibiotics aimed at treating multi-drug-resistant bacterial infections. Our primary focus is on addressing nosocomial infections, particularly complicated urinary tract infections (UTIs) and hospital or ventilator-

Available profile information

• Official website is captured for entity disambiguation.
• 1 official source linked for verification.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.